|
Synonyms: BIIB-059 | BIIB059
Compound class:
Antibody
Comment: Litifilimab (BIIB059) is a fully humanized IgG1, CLEC4C (blood dendritic cell antigen 2, BDCA2) targeting monoclonal antibody. It is being evaluated for ability to reduce release of disease-driving interferons (principally IFN-α) in SLE/CLE. BIIB059 was developed by Biogen, based on prior evidence of target engagement and SLE-applicable immunomodulatory efficacy of a humanized mAb against BDCA2 named 24F4A [3].
|
| Immunopharmacology Comments |
| BIIB059 is an investigational mAb targeting BDCA2, that is designed to disrupt type I IFN production by pDCs, as a disease-modifying mechanism to treat SLE. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Clinical lead for SLE and CLE. | |
